



**FOR IMMEDIATE RELEASE**

**AdvanSource Biomaterials' Antimicrobials Patent Application  
Published by U.S. Patent Office**

**AdvanSource Antimicrobial Polymers Targets Eradication of MRSA  
Clinical Infections Associated with Medical Devices**

**WILMINGTON, MA, January 6, 2009** --AdvanSource Biomaterials Corporation (NYSE **Alternext US: ASB**), a leading developer of advanced polymer materials for a broad range of medical devices, announced today notification of the publication by the U.S. Patent and Trademark Office of the Company's U.S. patent application related to antimicrobial polyurethane polymers.

The Company is developing a drug-free, antimicrobial technology to eradicate MRSA clinical infections associated with medical devices. The Company believes that infection rates from MRSA, primarily from hospitals and other medical facilities, pose significant risks to patient populations and are increasing in frequency.

The Patent Office is continuing its patent application review process which typically takes 12-24 months to complete. Recent changes to U.S. patent law relating to the publication of applications may entitle the Company to provisional rights in the form of reasonable royalties from the date of publication to the date the patent actually issues, although there can be no assurance that a patent will be issued.

Dr. Andrew Reed, Vice President of Science and Technology stated: "Our proprietary manufacturing process is differentiated by incorporating the antimicrobial agent during the synthesis process. These antimicrobial formulations are designed to possess a high degree of bacterial "kill." The materials may be used as structural components or as coatings in various catheters, including venous, arterial and urological."

The Company's antimicrobial polymers exhibit the following properties:

- The surface of components manufactured from its antimicrobial polymers are less susceptible to bacterial growth and biofilm formation, reducing the potential for foreign body patient infections, and
- The antimicrobial agent is uniformly dispersed throughout the polymer, providing long lasting activity.

**About AdvanSource Biomaterials Corporation**

AdvanSource Biomaterials Corporation manufactures advanced polymer materials which provide critical characteristics in the design and development of medical devices. The Company's biomaterials are used in devices that are designed for treating a broad range of anatomical sites and disease states. AdvanSource's business model leverages its proprietary materials science technology and manufacturing expertise in order to expand its product sales and royalty and license fee income. The Company is conducting a clinical trial for regulatory approval at two sites



in Europe for its CardioPass™ synthetic coronary bypass graft. More information about AdvanSource is available at its website: [www.advbiomaterials.com](http://www.advbiomaterials.com)

**Forward-Looking Statements:**

*AdvanSource believes that this press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause results to differ materially from the forward-looking statements. For further information on such risks and uncertainties, you are encouraged to review AdvanSource's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended March 31, 2008 and its Quarterly Reports for the periods ended June 30, 2008 and September 30, 2008. AdvanSource assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law.*

**For Further Information Contact:**

Eric Walters  
Vice President & CFO  
AdvanSource Biomaterials  
978-657-0075  
[info@advbiomaterials.com](mailto:info@advbiomaterials.com)

Sylvia Dresner  
Senior Vice President  
VMW Corporate & Investor Relations  
212-616-6161  
[info@vmwcom.com](mailto:info@vmwcom.com)